Eli Lilly and Company has reported findings from an indirect treatment comparison analysing data from the ACHIEVE-3 and PIONEER PLUS studies of its investigational therapy Foundayo (orforglipron) against oral semaglutide in adults with type 2 diabetes.
The analysis was announced at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan, Italy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The comparison assessed Foundayo 17.2mg and oral semaglutide 25mg over 52 weeks.
According to the findings, participants receiving Foundayo lost 1.5% more body weight on average than those taking oral semaglutide, with a reported 95% confidence interval of -2.7% to -0.2%.
For blood sugar control, Foundayo also produced a 0.3% greater reduction in A1C levels compared to oral semaglutide, within a 95% confidence interval of -0.6% to -0.1%. The analysis was covariate-adjusted for variables such as age, gender, baseline A1C, and starting weight.
Additional statistical methods confirmed the direction of these results, with observed differences in weight loss ranging from 1.5% to 2.4% and A1C reductions between 0.3% and 0.6% favouring Foundayo.
Lilly Cardiometabolic Health medical innovation and external engagement senior vice-president Rachel Batterham said: “Head-to-head trials ultimately provide the best comparison of two medicines, but when we don’t yet have those data, then other approaches can provide informative data points.
“Results from this indirect treatment comparison suggest that Foundayo may deliver A1C and weight lowering that is similar to the 25mg dose of oral semaglutide.
“These results, paired with simple administration free of fasting or water restrictions, are what make Foundayo a potentially foundational therapy for adults managing type 2 diabetes around the world.”
Foundayo is a once-daily oral glucagon-like peptide-1 receptor agonist, currently approved in the US for adults with obesity or overweight who have weight-related health issues, to support weight loss and maintenance when used alongside diet and exercise.
It was originally discovered by Chugai Pharmaceutical and licensed to Lilly in 2018. The ongoing ACHIEVE clinical trial programme for orforglipron has enrolled over 6,000 adults with type 2 diabetes globally.
In June this year, Lilly reported results from the BRUIN CLL-322 Phase III trial, assessing Jaypirca (pirtobrutinib), a non-covalent bruton tyrosine kinase (BTK) inhibitor, combined with venetoclax and rituximab against venetoclax and rituximab alone in patients with relapsed or refractory (r/r) chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL).
